Efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drug(s): the SoliD randomised controlled trial

被引：0
|
作者：
Li, Y. [1 ]
Gu, W. [2 ]
Chen, L. [3 ]
Kuang, H. [4 ]
Du, J. [5 ]
Alvarez, A. [6 ]
Lauand, F. [7 ]
Souhami, E. [7 ]
Zhang, J. [8 ]
Xu, W. [9 ]
Du, Q. [8 ]
Mu, Y. [2 ]
Liu, M. [10 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Endocrinol, Beijing, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Endocrinol, Jinan, Shandong, Peoples R China
[4] Harbin Med Univ, Affiliated Hosp 1, Dept Endocrinol, Harbin, Peoples R China
[5] Dalian Med Univ, Affiliated Hosp 1, Dept Endocrinol, Dalian, Liaoning, Peoples R China
[6] Sanofi, Madrid, Spain
[7] Sanofi, Paris, France
[8] Sanofi, Beijing, Peoples R China
[9] Sanofi, Shanghai, Peoples R China
[10] Tianjin Med Univ, Dept Endocrinol & Metab, Gen Hosp, Tianjin, Peoples R China
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
790
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)-The SoliD Randomized Controlled Trial
    Liu, Ming
    Gu, Weijun
    Chen, Li
    Li, Yanbing
    Kuang, Hongyu
    Du, Jianling
    Alvarez, Agustina
    Lauand, Felipe, Sr.
    Souhami, Elisabeth
    Zhang, Jiewen
    Xu, Weiya
    Du, Qin
    Mu, Yiming
    DIABETES, 2024, 73
  • [2] The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial
    Liu, Ming
    Gu, Weijun
    Chen, Li
    Li, Yanbing
    Kuang, Hongyu
    Du, Jianling
    Alvarez, Agustina
    Lauand, Felipe
    Souhami, Elisabeth
    Zhang, Jiewen
    Xu, Weiya
    Du, Qin
    Mu, Yiming
    DIABETES OBESITY & METABOLISM, 2024, 26 (09): : 3791 - 3800
  • [3] Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents
    Skolnik, Neil
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Meneghini, Luigi
    DIABETES, 2019, 68
  • [4] Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial
    Yang, Wenying
    Dong, Xiaolin
    Li, Qingju
    Cheng, Zhifeng
    Yuan, Guoyue
    Liu, Ming
    Xiao, Jianzhong
    Gu, Shenghong
    Niemoeller, Elisabeth
    Chen, Lijuan
    Ping, Lin
    Souhami, Elisabeth
    DIABETES OBESITY & METABOLISM, 2022, 24 (08): : 1522 - 1533
  • [5] Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
    Kaku, Kohei
    Yamada, Yuichiro
    Watada, Hirotaka
    Abiko, Atsuko
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kiyosue, Arihiro
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1202 - 1212
  • [6] The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec plus insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial
    Mu, Yiming
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5497 - 5499
  • [7] Efficacy and safety of diacerein in patients with inadequatedly controlled type 2 diabetes: a randomised controlled trial
    Cardoso, C. R. L.
    Leite, N. C.
    Salles, G. F.
    DIABETOLOGIA, 2017, 60 : S390 - S390
  • [8] Efficacy and safety of exenatide in Japanese patients with type 2 diabetes suboptimally controlled despite oral therapy
    Sowa, Hideaki
    Kadowaki, Takashi
    Namba, Mitsuyoshi
    Iwamoto, Kazuya
    Imaoka, Takeshi
    Yamamura, Ayuko
    Goto, Wakana
    Boardman, Marilyn
    ENDOCRINE JOURNAL, 2010, 57 : S362 - S362
  • [9] Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial
    Seufert, Jochen
    Wiesner, Tobias
    Pegelow, Katrin
    Kenzler, Julia
    Pfohl, Martin
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1526 - 1535
  • [10] Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin-A Systemic Literature Review and Network Meta-analysis
    Home, Philip
    Lauand, Felipe
    Djaballah, Khier
    Bourhis, Francois
    Li, Xuan
    Hafidh, Khadija
    Mehta, Roopa
    Faraoun, Khadra
    Anaforoglu, Inan
    Pourrahmat, Mir-Masoud
    DIABETES, 2024, 73
12345